Comparing Unicycive Therapeutics (UNCY) & Its Rivals

Unicycive Therapeutics (NASDAQ:UNCYGet Rating) is one of 939 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Unicycive Therapeutics to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Unicycive Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Unicycive Therapeutics N/A -$10.02 million -0.87
Unicycive Therapeutics Competitors $1.86 billion $249.36 million -1.72

Unicycive Therapeutics’ peers have higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Unicycive Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics 0 0 3 0 3.00
Unicycive Therapeutics Competitors 6379 20997 43228 867 2.54

Unicycive Therapeutics presently has a consensus target price of $8.25, suggesting a potential upside of 936.82%. As a group, “Pharmaceutical preparations” companies have a potential upside of 128.39%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Unicycive Therapeutics is more favorable than its peers.


This table compares Unicycive Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Unicycive Therapeutics N/A -113.11% -91.23%
Unicycive Therapeutics Competitors -3,144.42% -1,577.63% -9.15%

Institutional & Insider Ownership

19.3% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

About Unicycive Therapeutics (Get Rating)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with's FREE daily email newsletter.